drugset / Trial / NCT07141511
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
RandomizedSequentialOpen-labelOther
Summary
The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered simultaneously and the effect of food on how the body processes the fixed-dose combination tablet.
Timeline
- Start
- 2025-09-24
- Primary completion
- 2026-02-23
- Completion
- 2026-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG-71332 | Unknown | — | Oral |
| Subject | Sonrotoclax | Other / unclassified | — | Oral |
| Subject | Zanubrutinib | Small molecule | — | Oral |
Indications
No indication recorded.